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EFFECT OF A THROMBOLYTIC AGENT (UROKINASE)
ON NECROSIS AFTER ACUTE MYOCARDIAL
INFARCTIONI
W. T. HERMENS,2 S. A. G. J. WITTEVEEN,
L. HOLLAAR. and H. C. HEMKER2
SUMMARY
Us.lng a two-compartment model with continuous input function, the rate and extent of
myocardial damage were calculated from plasma enzyme levels measured in patients suffer-
ing from acute myocardial infarction (AMI). Results were compared for four different
enzymes. As regards the course of necrosis, two different hypotheses were tested and it was
shown that the necrotic process has to be considered as a multiplicative process rather than
as a sudden disintegration of cells due to anoxia. Comparison of results obtained in a group
of 5 patients treated with urokinase and in an untreated control group of 10 patients
showed that the necrotic phase as defined by the enzyme release from the infarcted area was
signifi cantly shortened,
INTRODUCTION
The importance of determining plasma enzyme levels in patients suffering from
acute myocardial infarction (AMI) has been well established. However, these
data arq mainly used in a qualitative way for diagnostic or prognostic reasons. As
the routine laboratory determinations of these enzymes are sufficiently accurate
to allow a thorough analysis of enzyme levels as a function of time, much
information is lost that way. In the last few years, we have developed a method
of obtaining a quantitative anlysis of myocardial damage after AMI (Hemker er
al., 1972; Witteveen, 1972). In the present paper, this method is used to
investigate the effect of urokinase on the necrotic process after AMI.
MATERIALS AND METHODS .
The experimental $oup consisted of 15 patients with AMI, of whom 5 received
urokinase. Patients with cardioeenic shock or severe heart failure were not
I Supported by the Dutch Heart Foundation.
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included in the investigation. For further clinical details see the publication by
Witteveen (1912).
Blood was drawn from an indwelling catheter as soon as possible aftel
admission to hospital and, subsequently, every 4 hours for 2 or 3 days' At the
end of this period, progressively fewer samples were taken until plasma levels
returned to normal.
Samples consisted of l0 ml of blood collected in tubes containing 0.2 ml of
20% sodium citrate to prevent clotting and were immediately centrifuged,
initially for 10 min at 900 g to remove erythrocytes and leukocytes' and
subsequently for 20 min at 40,000 g to remove thrombocytes. The plasma was
then stored at -20" C until enzyme determinations were carried out'
The following enzymes were studied: glutamic oxalacetic transaminase
(GOT: E.C.  2.6.1.1) ,  creat ine phosphokinase (CPK; E 'C'  2 '7 '3 '2) '  phospho-
hexose isomerase (PHI; E.C. 5.3.1.9), lactate dehydrogenase (LDH, E'C'
l.LI.27), and o'hydroxybutyrate dehydrogenase (a-HBDH; E'C' 1'l '1 '27)'TlrLe
last two enzymes are identical but are determined in a different assay, so that
comparison of results permits an estimation of over-all expelimental elrol.
Enzyme determinations were done spectrophotometrically. For GOT, LDH,
and 0-HBDH commercially available test kits were used (Boehringer). Recently,
Boehringer introduced so-called optimized test kits. If these ale used, the results
presented below should be adjusted. CPK was determined according to Rosalki,
(1967), and PHI according to Weber and Wegmann (1968). Enzyme activities
were expressed as LU./liter, in which I I.lJ. catalyzes the turnover of 1 prmole of
substrate per minute.
Urokinase, a nonantigenic thrombolytic agent acting through activation of
plasminogen, was made available by Hoffmann La Roche. The drug was adminis-
tered as soon as possible after admission to hospital. An initial loading dose of
7,200 units/kg body weight was given in 10 min, after which an infusion of
3,600 units/hour/kg body weight was given for 18 hours.
Heart tissue was obtained at thoracic surgery. To determine the enzyme
activities in the normal myocardium, the tissue was kept in physiological saline
at 0"C and homogenized within 10-15 min (Turrax). After sedimentation of the
remaining particles, the activities were measured in the supernatant (Table 2). To
study the stred-out of enzymes in vitro, tissue was kept at 37oC for up to 100
hours in plasma under anoxic conditions and gentle shaking;the activity appear-
ing in the plasma was measured. After this period, the tissue was homogenized to
obtain the residual tissue activity (Table l). The molecular weights of the human
enzymes were determined by column chromatography with DEAE Sephadex
G-200 of plasma containing high activities. To obtain a standard, albumin (M =
69,000) and ceruloplasmin (M = 160,000) were also determined by quantitative
immunoelectrophoresis ( La urel ).
The mathematical analysis of the patient data is based upon the two-compart-
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ment model presented in Figure 1, where Zr is the vascular volume, V2 the
extravascular volume, F(t) the enzyme release as a function of time, k the sum
of first order clearance constants, and D the diffusion constant. This model is
based upon the following considerations. The observed (double) exponential
clearance from the plasma indicates that there is only first order elimination
proportional to the enzyme concentration.
The assumption of the absence of extravascular elimination is based upon the
in vitro experiments showing no appreciable denaturation. This suggests that the
enzyme breakdown is circulation-dependent. Insofar as the enzymes from the
necrotic cells do not diffuse directly into the blood stream, we assumed that, in
view of the relatively direct transport of lymph from the myocardium to the
vascular compartment by way of the thoracic duct, the input F(t) is only into
/1 . A more detailed discussion of the implicit assumptions of this model will
be published elsewhere (Hermens et al.). It can be shown (Witteveen, 1972)
that the plasma concentration of ernyme as a function of time X(t) in ltns
model is given by the double exponential function
X(  t )=Cr ( t )e -a ' r  + ( r (  1 ) s -az t+1 ,
(a1 ) a2 ) 0), where X, is the normal steady state enzyffrcconcentration, and
the constants a1 alld a2 depend Qfi Vt, V2, k, and D. The time-dependent
coefficients in Eq. (1) are given by:
Cr(t)= l(q - oflzf k)l@, * ar)f [t fQ)eo,'{ (2)
Cr(t)= f(a1a2fk-a2)l@r-ar)l l t f(r)ro"d' (3)
where f(t) = F(t)lvfkxn = extla elzyme release (i.e., due to infarction) per
liter vascular volume.
As soon as the enzyme release from the infarcted area is completed, i.e.,
f(t) = 0, Clt) and Cz(t) become constants and a logarithmic plot gives a curve
with slopes a1 and a2 as shown in Figure l.
The vascular volume V1 was calculated from body weight and hematocrit. The
remaining parameters, k, V, , and permeability constant P (which is related to
the diffusion constant D by P = DS/6, where S and 6 ale the total interface area
and the characteristic thickness of the memblane between both compartments),
were obtained by curve-fitting techniques (Hermens et al., to be published).
However, an assumption has to be made regarding the release function/(r).
Two different hypotheses concerning // t ) were proposed as showin in Figure 2.
In case A, we assume that necrosis is a multiplicative process;i.e., local degrada-
tion of cells has an amplifying effect on the necrosis of adjacent tissue, for
instance, because of the release of cell contents, e.g', potassium. It can be shown
( r )
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(Aitchison and Brown, 1963)
normal function given by
that, under these circumstances, f(t) wrll be a log
f(t) = exp (- 0.5(Inr - p)' lo') (4)
This is a three-parameter function in which Q is the total extra release of enzyme
per liter vascular volume.
In case B, we assume that, after a period of ischemia, the majority of cells
become permeable in a relatively short lapse of time (for instance, in a few
minutes). This results in a sudden maximal release of diffusing enzymes with an
exponential fall-off which is described by the following function:
f(t)= Qbexp(b(t-tp)) tlz to (s)
which is again a three-parameter function with total release Q.
RESULTS
As reported earlier (Hemker et al. 1972), the biphasic disappearance shown in
Figure I is only observed for PHI, meaning that the plasma clearance curves for
CPK, GOT, and LDH (e-HBDH) are monoexponential. This phenomenon is
caused by the fact that the enzyme release from the infarcted tissue continues
for an appreciable period of time (about 34 hours for patients treated with
urokinase and about 48 hours for untreated patients; see Figure 5). Owing to
this tailing release, the fast phase of the clearance curve will not be observed in
INPUT F(r)
Figure 1. Two-compartment model.
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Figure 2. Two hypotheses regarding necrosis; A=multiplicative necrosis, B=sudden necrosis.
those cases where the exchange by diffusion (P) is fast compared to the
clearance (k).
PHI is the only enzyme which is metabolized fast enough to show a biphasic
disappearance of those patients with a relatively short period of enzyme release
(mostly urokinase-treated patients).
The results of curve fitting for PHI showed that, in all cases, the assumption of
multiplicative necrosis gave a better fit than the assumption of sudden necrosis;
for more details, see the work of Hermens et al. (to be published)'. The best fit
parameter values obtained for P and,Y2lYl are (for PHI):
P= 0.15 t 0.1 (liter/hour)
Vz lV ,  =0 .30  t  0 .12
For the molecular weights, the following values were found:
(6)
LDH(o-HBDH)
PHI
CPK
GOT
All values are i 5,000.
M = 145,000
M = 98,000
M = 82,000
M = 80,000
As the diffusion constalts of proteins are not very sensitive to molecular
weight (Schultze and Heremans, 1966), it is improbable that the values for p and
V2ln wfi, differ much from those found for PHI. Values (6)were therefore used
in a routine computer program for all enzymes. In this program, the slow phase
of the clearance curve is used to calculate k Subsequently, the extravascular
concentrations, the release function f(t), and the total release are calculated
from the plasma concentrations. The results are shown in Figure 3.
TIME ( t )
F(t)
TIME f t )
J L + W. T. Hermens ef a/.
Figure 3. Patient 8. 1 = measured plasma concentrations. 2 = calculated extravascular
concentrations.3 = calculated enzyme release/hour. 4 = calculated total enzyme release.
Figure 4 shows the corlelations between the calculated total release Qfor Ihe
different enzymes compared to LDH. As the clearance.for LDH (0-HBDH) is
slow (cf. Table 3), this enzyme is the least sensitive to the irregularities in the
release and was therefore chosen as reference. The systematic error in Q"o,
corresponding to the uncertainty in P and V2 lV1 is estimated aI lO-15%'
The correlation for CPK is not satisfactory, possibly attributable to the fact
that this is the only enzyme that showed an unpredictable denaturation during
in vitro studies (Witteveen, 1972). This phenomenon could invalidate our as-
sumption of absence of extravascular elimination for this enzyrne-
The results of four in vitro experiments of anoxic incubation of tissue ale
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Figure 4. Correlations $etween calculated total enzyme release. Best fif straight line
through the origin for c-HBDH: y = 0.74x;GOT: y=g.22ri CPK: y=1.56r; PHI: y=6.99".
0.89 x.
shown in Table l. As seen from Figure 4 and rable 1, the calculated total
amounts of enzyme released from the infarcted area in patients exhibit approxi-
mately the same ratio as the amounts released invitro. However, if we compare
these nr vitro values with the activities measured in fresh tissue (Table 2), we
find that, for LDH (a-HBDII) and PHI, the original activities are recovered but,
for GOT and CPK, roughly one-third of the activity has disappeared by a local
process which apparently (also) proceeds in vitro.
Table 3 shows the calculated clearance constaxts k, total enzyme release e,
and equivalent amount of heart tissue ,4 in grams for all patients except patient
15; in this patient, the levels were too low to permit calculation of LDH. GOT.
and PHI.
*1
I
.tq.
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Table 1. [n vitro enzyme release from human heart tissue incubated in
plasma*
LDH c-HBDH GOT CPK PHI
E x p e r i m e n t A B A B A B A B A B
1
2
A
t 2 2  2 1  9 9  1 9
136 23 87 16
127  33  87  2 l
89  20  64  15
r 1 8  2 4  8 4  1 8
43  22  261  71  t l 2  t 9
23  28  88  37  84  19
35  37  126  36  120  28
32 42 164 96 106'  t9
34  32  160  60  105  2 lMean:
* Activities expressed in I.U./g wet tissue. A, activity in plasma; B, residual tissue
activity after 100 hours' incubation.
The amounts A were calculated for LDH by multiplying Qtott by 1.20 Io
account for the residual tissue activity (see Table 1) and by the vascular volume,
and dividing by 128 (see Table 2). For the other enzymes, the calculated Q was
first transformed into the corresponding Qlps by means of the best fit
equations given in Figure 4, followed by the same procedure. The effect of
urokinase is shown in two ways. Table 4 gives the time of maximal plasma
activity in hours after the onset of severe symptoms. As can be seen from this
table, there is a considerable shortening for patients treated with urokinase. The
same phenomenon is observed in Figure 5, where the calculated enryme release
f(t) n l.U .lliter/h.ours has been averaged for each group of patients.
DISCUSSION
The effect of urokinase in patients presenting electrocardiographic evidence of
necrosis, such as elevation of the ST-segment, has been revealed in the multi-
centered European Urokinase Trial in myocardial infarction. It could be demon-
Table 2. Human heart tissue enzvme activitv*
LDH o-HBDH GOT CPK PHI
Mean 128
s.D.  15.4
to l  96 370 t43
I  1.1 18.2 3 ' t  .O 14.3
*Activities expressed in I.U./g wet tissue (results of 15
determinations).
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Table 4. Time of maximal plasma enzyme activity*
LDH o-HBDH GOT CPK
37.7  (6 .3 )  3e . l  (7 .0 )  27 .6  (4 .e )  22 .e  (s .4 )  22 .2  (s .3 )
2s.7 (6.3) 2s.7 (6.3) 19.6 (4.2) r7.3 (3.6) 16.8 (2.8)
*Values are expressed as means, with S.D. shown in parentheses. A, mean
value for control patients (11/ = 10); B, mean value for patients treated with
urokinase (1f = 5). Difference between A and B is significant at a 0.02 level for
LDH, c-HBDH, and GOT, and, at a 0.05 level for CPK and PHI (Wilcoxon).
strated that the electrocardiogram of patients treated with urokinase showed a
more rapid normalization of the ST-segment as compared to the control group
(Burkart et al., 1973).
As yet, no important therapeutic advantages of thrombolytic agents have been
shown for AMI. Clinical trials on urokinase and another thrombolytic agent,
streptokinase, revealed no appreciable effect on mortality in patients treated in
coronary care units. In some earlier studies(Verstraete, 1973)nwhichpatients
were not treated in coronary care units, a favorable effect was found in trials
with streptokinase. Whether this effect implies that there have been fewer fatal
arrhythmias in the treated group, a finding which could be explained, for
example, by a shorter period of tissue necrosis and, thus, a shorter period of
electrical instability, remains to be demonstrated.
The two largest infarctions were found in urokinase-treated patients, with the
result that this group showed a somewhat larger average enzyme release than did
the control group. This qffect is not sigrificant in a rank test (see Tatle 4) and
PHI
A
B
I RELEASE of LDH
twt- l t rr ' , / tY o' ' t "" t"" 'H'"" :""0". : : tJ
t j  
I  \  
B:controrpat ients(n:s)
.J i ' r'i /\
4 |,"-E\---
I ti \'i L/ \
Fipre 5. Averaged release functions f(t) for LDH.
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might have been caused by the fact that the urokinase treatment was given to
early recogtized and hospitalized patients, the group that tends to present the
larger infarctions. However, it remains to be answered whether urokinase, apart
from accelerating the enzyme release, could also enhance it.
As regards the quantitation of the amount of necrotic tissue, it should be
noted that, although we account for the amount of enzyme that is not released
in vitro (20% for LDH) and although the release in vitro shows the same ratio for
the amounts of different enzymes as the release in vivo, there might be an
over-all underestimation due to local in vivo breakdown of tissue, e.g., by
infl ammatory processes.
Experiments in which CPK release was studied after experimental AMI in dogs
showed that less than 30% of total tissue CPK appeared in the circulation (Shell,
Kjekshus, and Sobel, 1971). However, the time course of plasma enzyme activity
in dogs differs considerably from that in man; therefore, caution should be used
before applying these data in studies of infarction in man.
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